2014
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke 2014, 45: 2160-2236. PMID: 24788967, DOI: 10.1161/str.0000000000000024.Peer-Reviewed Original ResearchConceptsTransient ischemic attackEvidence-based recommendationsIschemic attackCerebral venous sinus thrombosisTimely evidence-based recommendationsAntiphospholipid antibody syndromeVenous sinus thrombosisPrevention of strokeAortic arch atherosclerosisSickle cell diseaseImplementation of guidelinesAntibody syndromeFuture strokeRecurrent strokeAnticoagulation therapyAntiplatelet therapyAntithrombotic therapySinus thrombosisIschemic strokeNoncardioembolic strokeSecondary preventionArterial dissectionHypercoagulable statePatent foramenIntracranial hemorrhage
2009
The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics
Bushnell C, Zimmer L, Schwamm L, Goldstein L, Clapp-Channing N, Harding T, Drew L, Zhao X, Peterson E. The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics. American Heart Journal 2009, 157: 428-435.e2. PMID: 19249411, DOI: 10.1016/j.ahj.2008.11.002.Peer-Reviewed Original ResearchConceptsIschemic stroke Longitudinal (AVAIL) registryTransient ischemic attackIschemic attackRecurrent strokePrevention medicationsLongitudinal registryAdherence evaluationSecondary preventive therapyBaseline patient characteristicsModified Rankin scoreSecondary prevention measuresMedication-taking behaviorSystem-level barriersLevel of adherenceFuture strokeCardiovascular eventsRankin scoreVascular eventsAcute hospitalizationHospital dischargePatient characteristicsPreventive therapySecondary outcomesMedication usePrimary outcome